{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T03:25:40Z","timestamp":1789010740836,"version":"build-2803163510"},"reference-count":33,"publisher":"American Society of Hematology","issue":"3","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,2,11]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>Anthracycline-mediated cardiotoxicity is a common concern after lymphoma therapy, particularly in patients with high cardiovascular risk (CVR). In noncancer populations, coronary artery calcium scoring (CACS) effectively identifies individuals who may benefit from aggressive CVR modification to lower the risk of cardiovascular events. Emerging evidence suggests that CACS can also predict cancer therapy-related cardiotoxicity, potentially identifying candidates for cardioprotective strategies. Our study aimed to evaluate whether CACS obtained from pretreatment positron emission tomography (PET)\/computed tomography (CT) scans could stratify cardiac event risk in patients with lymphoma receiving anthracycline-based chemotherapy. We enrolled 358 consecutive patients with lymphoma treated between 2012 and 2022, calculating the CACS from their pretreatment PET\/CT. We reviewed medical records to identify pre-existing cardiac conditions, CVR, and posttreatment cardiac events, including coronary events, heart failure (HF), and arrhythmias. Logistic and Cox regression models were used to assess associations between CVR, CACS categories (CACS\u00a0=\u00a00, CACS 1-400, CACS &amp;gt;400), and new cardiac events. At a median follow-up of 27\u00a0months (95% confidence interval [CI], 22.3-31.7) in patients without cardiac history, 10% experienced posttreatment cardiac events (HF, 14; arrhythmias, 9; coronary event, 1; combination, 8). Patients with a CACS &amp;gt;0 had more events (21 total, 20% vs 11 total, 5.4% for CACS\u00a0=\u00a00; P\u00a0&amp;lt; .001). Elevated CACS was independently associated with HF (CACS 1-400: odds ratio [OR], 3.73; 95%\u00a0CI, 1.21-11.43; P\u00a0=\u00a0.022; CACS &amp;gt;400: OR, 5.43; 95%\u00a0CI, 1.47-20.03; P\u00a0=\u00a0.011) and any cardiac event (CACS 1-400: OR, 2.48; 95%\u00a0CI, 1.02-6.04; P\u00a0=\u00a0.045; CACS &amp;gt;400: OR, 3.28; 95%\u00a0CI, 0.91-10.68; P\u00a0=\u00a0.029). CACS may effectively stratify patients with lymphoma at risk of cardiac complications, thereby identifying a group poised to benefit from targeted preventive strategies.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/bloodadvances.2024013620","type":"journal-article","created":{"date-parts":[[2024,11,22]],"date-time":"2024-11-22T21:14:01Z","timestamp":1732310041000},"page":"499-506","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":1,"title":["PET\/CT-derived coronary calcium score may predict cardiac complications in anthracycline-treated patients with lymphoma"],"prefix":"10.1182","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5951-7907","authenticated-orcid":false,"given":"Genevieve","family":"Douglas","sequence":"first","affiliation":[{"name":"1Department of Clinical Haematology, Austin Health, Heidelberg, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zoe","family":"Loh","sequence":"additional","affiliation":[{"name":"1Department of Clinical Haematology, Austin Health, Heidelberg, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evonne S.Y.","family":"Shum","sequence":"additional","affiliation":[{"name":"2Department of Molecular Imaging and Therapy, Austin Health, Heidelberg, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sze-Ting","family":"Lee","sequence":"additional","affiliation":[{"name":"2Department of Molecular Imaging and Therapy, Austin Health, Heidelberg, Australia"},{"name":"3Lymphoma Clinical Innovations Group, Olivia Newton John Cancer and Research Institute, Austin Health, Heidelberg, Australia"},{"name":"4Department of Medicine, University of Melbourne, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niamh","family":"Waters","sequence":"additional","affiliation":[{"name":"3Lymphoma Clinical Innovations Group, Olivia Newton John Cancer and Research Institute, Austin Health, Heidelberg, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8900-7529","authenticated-orcid":false,"given":"Garry","family":"Hamilton","sequence":"additional","affiliation":[{"name":"3Lymphoma Clinical Innovations Group, Olivia Newton John Cancer and Research Institute, Austin Health, Heidelberg, Australia"},{"name":"5Department of Cardiology, Austin Health, Heidelberg, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4006-2380","authenticated-orcid":false,"given":"Geoffrey","family":"Chong","sequence":"additional","affiliation":[{"name":"3Lymphoma Clinical Innovations Group, Olivia Newton John Cancer and Research Institute, Austin Health, Heidelberg, Australia"},{"name":"4Department of Medicine, University of Melbourne, Melbourne, Australia"},{"name":"6Department of Medical Oncology, Austin Health, Heidelberg, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4248-7537","authenticated-orcid":false,"given":"Alexandra C.","family":"Murphy","sequence":"additional","affiliation":[{"name":"3Lymphoma Clinical Innovations Group, Olivia Newton John Cancer and Research Institute, Austin Health, Heidelberg, Australia"},{"name":"5Department of Cardiology, Austin Health, Heidelberg, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0376-2559","authenticated-orcid":false,"given":"Eliza A.","family":"Hawkes","sequence":"additional","affiliation":[{"name":"1Department of Clinical Haematology, Austin Health, Heidelberg, Australia"},{"name":"3Lymphoma Clinical Innovations Group, Olivia Newton John Cancer and Research Institute, Austin Health, Heidelberg, Australia"},{"name":"4Department of Medicine, University of Melbourne, Melbourne, Australia"},{"name":"6Department of Medical Oncology, Austin Health, Heidelberg, Australia"},{"name":"7Department of Public Health and Preventative Medicine, Monash University, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2025,1,30]]},"reference":[{"key":"2025032119364059200_bib1","year":"2020"},{"key":"2025032119364059200_bib2","year":"2020"},{"issue":"7","key":"2025032119364059200_bib3","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1182\/blood-2005-08-3392","article-title":"Long-term risk of cardiovascular disease after treatment for aggressive non-Hodgkin lymphoma","volume":"107","author":"Moser","year":"2006","journal-title":"Blood"},{"issue":"5","key":"2025032119364059200_bib4","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1182\/blood-2006-07-034405","article-title":"Late cardiotoxicity after treatment for Hodgkin lymphoma","volume":"109","author":"Aleman","year":"2007","journal-title":"Blood"},{"issue":"6","key":"2025032119364059200_bib5","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1001\/jamainternmed.2015.1180","article-title":"Cardiovascular disease after Hodgkin lymphoma treatment: 40-year disease risk","volume":"175","author":"van Nimwegen","year":"2015","journal-title":"JAMA Intern Med"},{"issue":"10203","key":"2025032119364059200_bib6","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/S0140-6736(19)31674-5","article-title":"Medium and long-term risks of specific cardiovascular diseases in survivors of 20 adult cancers: a population-based cohort study using multiple linked UK electronic health records databases","volume":"394","author":"Strongman","year":"2019","journal-title":"Lancet"},{"issue":"5","key":"2025032119364059200_bib7","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1111\/bjh.15603","article-title":"Cumulative anthracycline exposure and risk of cardiotoxicity; a Danish nationwide cohort study of 2440 lymphoma patients treated with or without anthracyclines","volume":"183","author":"Baech","year":"2018","journal-title":"Br J Haematol"},{"issue":"4","key":"2025032119364059200_bib8","doi-asserted-by":"crossref","first-page":"e295","DOI":"10.1016\/S2352-3026(20)30031-4","article-title":"Cardiovascular adverse events in patients with non-Hodgkin lymphoma treated with first-line cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or CHOP with rituximab (R-CHOP): a systematic review and meta-analysis","volume":"7","author":"Linschoten","year":"2020","journal-title":"Lancet Haematol"},{"issue":"2","key":"2025032119364059200_bib9","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.ancard.2006.02.005","article-title":"Preventing the cardiotoxic effects of anthracyclins. From basic concepts to clinical data","volume":"55","author":"Delemasure","year":"2006","journal-title":"Ann Cardiol Angeiol"},{"key":"2025032119364059200_bib10","doi-asserted-by":"crossref","first-page":"736854","DOI":"10.3389\/fcvm.2021.736854","article-title":"Risk factors for anthracycline-induced cardiotoxicity","volume":"8","author":"Qiu","year":"2021","journal-title":"Front Cardiovasc Med"},{"key":"2025032119364059200_bib11","doi-asserted-by":"crossref","first-page":"1101585","DOI":"10.3389\/fcvm.2023.1101585","article-title":"Risk factors from Framingham risk score for anthracyclines cardiotoxicity in breast cancer: a systematic review and meta-analysis","volume":"10","author":"Jin","year":"2023","journal-title":"Front Cardiovasc Med"},{"key":"2025032119364059200_bib12","doi-asserted-by":"crossref","first-page":"736854","DOI":"10.3389\/fcvm.2021.736854","article-title":"Risk factors for anthracycline-induced cardiotoxicity","volume":"8","author":"Qiu","year":"2021","journal-title":"Front Cardiovasc Med"},{"issue":"22","key":"2025032119364059200_bib13","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1161\/CIRCULATIONAHA.114.013777","article-title":"Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy","volume":"131","author":"Cardinale","year":"2015","journal-title":"Circulation"},{"issue":"2","key":"2025032119364059200_bib15","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1001\/jama.291.2.210","article-title":"Coronary artery calcium score combined with Framingham score for risk prediction in asymptomatic individuals","volume":"291","author":"Greenland","year":"2004","journal-title":"JAMA"},{"issue":"18","key":"2025032119364059200_bib16","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1016\/j.jacc.2006.10.079","article-title":"Long-term prognosis associated with coronary calcification: observations from a registry of 25,253 patients","volume":"49","author":"Budoff","year":"2007","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"5","key":"2025032119364059200_bib17","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1093\/aje\/kwi228","article-title":"Coronary artery calcium score and coronary heart disease events in a large cohort of asymptomatic men and women","volume":"162","author":"LaMonte","year":"2005","journal-title":"Am J Epidemiol"},{"key":"2025032119364059200_bib18","unstructured":"Australian Government Department of Health and Aged Care\n          . Australian guideline for assessing and managing cardiovascular disease risk 2023. Accessed 3 February 2024. https:\/\/d35rj4ptypp2hd.cloudfront.net\/pdf\/Guideline-for-assessing-and-managing-CVD-risk_20230522.pdf."},{"issue":"9","key":"2025032119364059200_bib19","doi-asserted-by":"crossref","first-page":"434","DOI":"10.5694\/mja2.51039","article-title":"National Heart Foundation of Australia: position statement on coronary artery calcium scoring for the primary prevention of cardiovascular disease in Australia","volume":"214","author":"Jennings","year":"2021","journal-title":"Med J Aust"},{"issue":"2","key":"2025032119364059200_bib20","doi-asserted-by":"crossref","first-page":"e014829","DOI":"10.1161\/CIRCIMAGING.122.014829","article-title":"Cardiovascular risk stratification by automatic coronary artery calcium scoring on pretreatment chest computed tomography in diffuse large B-cell lymphoma receiving anthracycline-based chemotherapy: a multicenter study","volume":"16","author":"Shen","year":"2023","journal-title":"Circ Cardiovasc Imaging"},{"issue":"7","key":"2025032119364059200_bib21","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1001\/jamaoncol.2021.1144","article-title":"Identification of risk of cardiovascular disease by automatic quantification of coronary artery calcifications on radiotherapy planning CT scans in patients with breast cancer","volume":"7","author":"Gal","year":"2021","journal-title":"JAMA Oncol"},{"issue":"1","key":"2025032119364059200_bib22","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.radonc.2017.10.009","article-title":"Is the coronary artery calcium score associated with acute coronary events in breast cancer patients treated with radiotherapy?","volume":"126","author":"Roos","year":"2018","journal-title":"Radiother Oncol"},{"issue":"1","key":"2025032119364059200_bib23","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.ijrobp.2021.08.017","article-title":"Coronary artery calcifications and cardiac risk after radiation therapy for stage III lung cancer","volume":"112","author":"Wang","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"9","key":"2025032119364059200_bib24","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/j.jcmg.2012.03.016","article-title":"Coronary calcification and the risk of heart failure in the elderly: the Rotterdam Study","volume":"5","author":"Leening","year":"2012","journal-title":"JACC Cardiovasc Imaging"},{"issue":"4","key":"2025032119364059200_bib25","doi-asserted-by":"crossref","first-page":"e005253","DOI":"10.1161\/JAHA.116.005253","article-title":"Progression of coronary artery calcium and incident heart failure: the Multi-Ethnic Study of Atherosclerosis","volume":"6","author":"Bakhshi","year":"2017","journal-title":"J\u00a0Am Heart Assoc"},{"issue":"3","key":"2025032119364059200_bib26","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1161\/01.CIR.97.3.282","article-title":"Chronic heart failure in the United States: a manifestation of coronary artery disease","volume":"97","author":"Gheorghiade","year":"1998","journal-title":"Circulation"},{"issue":"8","key":"2025032119364059200_bib27","doi-asserted-by":"crossref","first-page":"357","DOI":"10.5694\/mja16.01134","article-title":"Cardiac Society of Australia and New Zealand position statement executive summary: coronary artery calcium scoring","volume":"207","author":"Hamilton-Craig","year":"2017","journal-title":"Med J Aust"},{"issue":"3","key":"2025032119364059200_bib28","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1161\/CIRCOUTCOMES.113.000690","article-title":"Use of coronary artery calcium testing to guide aspirin utilization for primary prevention: estimates from the multi-ethnic study of atherosclerosis","volume":"7","author":"Miedema","year":"2014","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"2","key":"2025032119364059200_bib29","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1001\/jamacardio.2020.4939","article-title":"Value of coronary artery calcium scanning in association with the net benefit of aspirin in primary prevention of atherosclerotic cardiovascular disease","volume":"6","author":"Ajufo","year":"2021","journal-title":"JAMA Cardiol"},{"issue":"19","key":"2025032119364059200_bib30","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1161\/CIRCULATIONAHA.119.045010","article-title":"Coronary artery calcium for personalized allocation of aspirin in primary prevention of cardiovascular disease in 2019: the MESA Study (Multi-Ethnic Study of Atherosclerosis)","volume":"141","author":"Cainzos-Achirica","year":"2020","journal-title":"Circulation"},{"issue":"25","key":"2025032119364059200_bib31","doi-asserted-by":"crossref","first-page":"3233","DOI":"10.1016\/j.jacc.2018.09.051","article-title":"Impact of statins on cardiovascular outcomes following coronary artery calcium scoring","volume":"72","author":"Mitchell","year":"2018","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"15","key":"2025032119364059200_bib32","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1016\/j.jacc.2015.07.066","article-title":"Implications of coronary artery calcium testing among statin candidates according to American College of Cardiology\/American Heart Association Cholesterol Management Guidelines: MESA (Multi-Ethnic Study of Atherosclerosis)","volume":"66","author":"Nasir","year":"2015","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"6","key":"2025032119364059200_bib33","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1001\/jama.2023.11887","article-title":"Atorvastatin for anthracycline-associated cardiac dysfunction: the STOP-CA Randomized Clinical Trial","volume":"330","author":"Neilan","year":"2023","journal-title":"JAMA"},{"issue":"41","key":"2025032119364059200_bib34","doi-asserted-by":"crossref","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","article-title":"2022 ESC guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)","volume":"43","author":"Lyon","year":"2022","journal-title":"Eur Heart J"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/3\/499\/2353588\/blooda_adv-2024-013620-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/3\/499\/2353588\/blooda_adv-2024-013620-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,21]],"date-time":"2025-03-21T20:02:27Z","timestamp":1742587347000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/9\/3\/499\/526132\/PET-CT-derived-coronary-calcium-score-may-predict"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,30]]},"references-count":33,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,2,11]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2024013620","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,30]]}}}